Sandford D. Smith
Interim Chief Executive Officer
Sandy Smith was appointed as Interim CEO in July of 2015. He has been a member of Aegerion's Board of Directors since 2012. Mr. Smith was most recently Executive Vice President and President International Group for Genzyme Corporation (Genzyme), where he was a member of the company's Executive Committee. As President of the International Group, Mr. Smith grew Genzyme's offshore revenue to 65 percent of Genzyme's nearly $5 billion revenues. During his tenure, Mr. Smith was responsible for the successful global launch of 12 new products in various therapeutic categories, including rare diseases. Mr. Smith joined Genzyme in 1996, and served as Vice President and General Manager of Genzyme International and President of Genzyme Specialty Therapeutics before being named to his most recent position. Following Sanofi's acquisition of Genzyme in April of 2011, Mr. Smith was responsible for the integration of Genzyme's international business into the Sanofi global organization. Prior to joining Genzyme, Mr. Smith was President and Chief Executive Officer at Repligen Corporation. Under his leadership, Repligen completed several secondary stock offerings, raising more than $100 million, and established important partnerships with Merck, Eli Lilly, Gillette, and Centocor/Johnson & Johnson. He also held several international leadership positions within Bristol Myers Squibb. Mr. Smith has served as a Director on a number of boards of both public and private healthcare companies, including Ariad Pharmaceuticals, NVenta and BioBehavioral Diagnostics. He currently is a member of the Board of Trustees of Brigham and Women's Hospital in Boston.
Will Andrews, MD, FACP
Senior Vice President, Business Development
William “Will” Andrews was appointed Senior Vice President of Business Development in May 2014. Dr. Andrews assumed the business development role after having spent two years as Vice President of Medical Affairs for Aegerion, starting and building the Medical Affairs function and overseeing medical affairs activities for the launch of JUXTAPID® in the United States, Canada, Latin America, and Asia. Prior to joining Aegerion in 2012, Dr. Andrews held Medical Affairs leadership roles with Santhera Pharmaceuticals and Sepracor. Before that, he was Medical Director at ClinQuest, where he worked on the Clinical Development of multiple innovative therapies and programs. Prior to joining the biopharmaceutical industry over 15 years ago, Dr. Andrews practiced Internal Medicine in Boston at Harvard Vanguard Medical Associates and Brigham and Women’s Hospital. He has also served as Clinical Instructor of Internal Medicine at Harvard Medical School and Attending Physician of Internal Medicine at Brigham and Women’s Hospital. Dr. Andrews received his Doctor of Medicine degree from Yale University School of Medicine, and his Bachelor of Arts degree in Biology from Harvard University.
Chief Regulatory Officer
Martha Carter was appointed Chief Regulatory Officer of Aegerion in February 2011, bringing over 30 years of regulatory affairs experience in prescription and over-the-counter drugs, biologics, biotechnology products, and medical devices. Prior to joining Aegerion, Martha was Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. where she was responsible for the company's worldwide regulatory and quality functions. Prior to this role, she was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to that, Martha was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. In this role, she led the company's regulatory and quality control functions for both commercial and investigational drug products. Martha is a Fellow of the Regulatory Affairs Professionals Society, and is a past President and Chairman of the Board. She is also a former member of the Editorial Advisory Board for Applied Clinical Trials and BioPharm. Martha holds a B.A. in Biology from Northeastern University.
Chief Financial Officer
Gregory Perry was appointed Chief Financial Officer of Aegerion in July of 2015. Mr. Perry most recently served as Chief Financial Officer of Eleven Biotherapeutics. Prior to joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics. Prior to joining InVivo, he served as the Executive Vice president and Chief Financial Officer of ImmunoGen. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr. Perry previously was Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer, Honeywell and General Electric. Mr. Perry serves on the board of directors of Ocata Therapeutics.
Mark Sumeray, MD, MS, FRCS
Chief Medical Officer
Dr. Sumeray brings development, regulatory and medical affairs experience with cardiovascular drugs such as Plavix®, apixaban, Avapro®/Avalide®, and Angiomax® to Aegerion. Dr. Sumeray was most recently Vice President Cardiovascular/Metabolics U.S. Medical, at Bristol-Myers Squibb. In this role, he was responsible for U.S. medical strategy for the CV and metabolics medical strategy teams, including implementation across the medical affairs function working collaboratively with marketing, sales, global clinical research and health outcomes. Prior to this role, Dr. Sumeray held several positions of increasing responsibility within The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President Medical Business Development, and Vice President Clinical Development and Head of Medical Science. Prior to that, Dr. Sumeray was worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson.
Senior Vice President, Human Resources
Mary Weger was appointed Senior Vice President, Human Resources in December, 2011. Mary brings over 30 years of Human Resource experience, eleven of which has been within the biopharmaceutical industry. Prior to joining Aegerion, Mary was Senior Vice President, Global Clinical Development Strategy & Effectiveness at Celgene Corporation. Prior to this appointment, she held the position of Senior Vice President, Global Human Resources at Celgene where she played an instrumental role in helping to build Celgene globally from a company with 150+ employees to a world-wide organization with revenue of over 4 billion and operations in over 30 countries. Prior to Celgene, Mary held positions of increasing responsibility at Kraft Foods Nabisco. She received her Masters certificate and Black Belt in Six Sigma in 2011 from Villanova University and also possesses a MA in Human Resource Management as well as having completed the Executive Human Resources program at Michigan University. Mary currently serves on the Board of Family Promise, a non-profit organization addressing the needs of homeless families.